Faculty Summaries
Dr. Robert G. Uzzo
Robert G Uzzo, MD, FACS
  • Co-Leader, Personalized Kidney Cancer Therapy Keystone

Publications

  • Kutikov A, Piotrowski ZJ, Canter DJ, Li T, Chen DYT, Viterbo R, Greenberg RE, Boorjian SA, Uzzo RG. Routine Adrenalectomy is Unnecessary during Surgery for Large and/or Upper Pole Renal Tumor when the Adrenal is Radiographically Normal. Journal of Urology, in press.
  • Golovine K, Makhov P, Uzzo RG, Kutikov A, Kaplan DJ, Fox E, Kolenko V: Cadmium down-regulates expression of XIAP at the post-transcriptional level in prostate cancer cells through an NF-κB-independent, proteasome-mediated mechanism. Molecular Cancer 9(1):183, 2010.
  • Lane BR, Russo P, Uzzo RG, Hernandez AV, Boorjian SA, Thompson RH, Fergany AF, Love TE, Campbell SC: Comparison of warm and cold ischemia during open partial nephrectomy for tumor in a solitary kidney. J Urol, (submitted), 2010.
  • Gupta V, Simons JD, Bassi DE, Al-Saleem TI, Uzzo RG, Cukierman E: Fibroblast-derived 3-D matrix system mimics in vivo stromal changes during renal cell carcinoma progression. J Am Soc Nephrol, (submitted), 2010.
  • Canter D, Kutikov A, Uzzo RG, Greenberg RE, Viterbo R, Fang Z, Chen DYT, Wong YN, Plimack E: Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally impacted by radical cystectomy. Urology, [E-pub ahead of print], 2010.
  • Piotrowski Z, Canter DJ, Kutikov A, Al-Saleem T, Testa J, Uzzo RG: The Metanephric Adenofibroma: Robotic partial nephrectomy of a Large Benign Wilms’ Tumor Variant. Canadian J Urol, 17:5309, 2010.
  • Boorjian SA, Uzzo RG: The case for active surveillance of the small renal mass. J Urol, (in press), 2010.
  • Giri, VN, Ruth, K, Hughes, L, Uzzo, RG, Chen, DYT, Boorjian, SA, Viterbo, R, and Rebbeck, TR. Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: Effect of TMPRSS2 Met160Val. BJU Intl,[E-pub ahead of print], 2010.
  • Long CJ, Kutikov A, Canter DJ, Egleston, Chen DYT, Viterbo R, Boorjian SA, Uzzo RG: Percutaneous versus Surgical Cryoablation of the Small Renal Mass: Is Efficacy Compromised? BJU Intl, (in press), 2010.
  • Canter D, Long C, Kutikov A, Plimack E, Zhu F, Viterbo R, Chen DYT, Uzzo RG, Greenberg RE, Boorjian SA: Clinicopathological Outcomes after Radical Cystectomy for Patients with Clinical T2 Urothelial Carcinoma: Further Evidence to Support the Use of Neoadjuvant Chemotherapy, BJU Intl,[E-pub ahead of print], 2010.
  • Aron M, Gill IS, Boorjian SA, Uzzo RG: Treatment of the 2 to 3cm Renal Mass. J Urol, [E-pub ahead of print], 2010
  • Brien JC, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD: Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper-tract urothelial carcinoma. J Urol, 184 (1):69-73, 2010.
  • Campbell SC, Derweesh IH, Faraday MM, Uzzo RG: re: Gill, et al: Small Renal Mass. N Engl J Med, 362; 24:2334-5, 2010.
  • Campbell SC, Faraday M, Uzzo RG, Gill IS, Aron M, Jewett MAS: Small Renal Mass. N Engl J Med, 362; 24:2334-5, 2010.
  • Pei J, Feder MM, Al-Saleem T, Liu Z, Liu A, Hudes GR, Uzzo RG, Testa JR: Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma. Genes Chromosomes Cancer, 49(7):610-9, 2010.
  • Kutikov A, Egleston BL, Wong YN, Uzzo RG: Reply to J. Lagro et al and G. Lughezzani et al, J Clin Oncol, 28:e301, 2010.
  • Sharma NK, Eade TN, Buyounouski MK, Jinsheng L, McNeeley S, Crawford K, Chen DYT, Uzzo RG, Horwitz EM: An Intra-Operative real-time sleeved seed technique for permanent prostate brachytherapy. Brachytherapy, 9(2):126-30, 2010.
  • Lebed B, Jani SD, Kutikov A, Iffrig K, Uzzo RG: Renal Masses Herniating into the Hilum: Technical Considerations of the "Ball-Valve Phenomenon" During Nephron Sparing Surgery. Urology, 75(3):707-10, 2010. (cover featured article)
  • Toujer K, Jacqmin D, Kavoussi LR, Montorsi F, Patard JJ, Rogers CG, Russo P, Uzzo RG, Van Poppel H: The expanding Role of Partial Nephrectomy: A Critical Analysis of Indications, Results, and Complications. Eur Urol, 57 (2):214-22, 2010.
  • Kutikov A, Egleston BL, Wong YN, Uzzo RG: Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Onc, 28(2):311-7, 2010.
  • Kutikov A, Uzzo RG: Moving Forward: Objectifying Criteria for Partial Nephrectomy (editorial). Urology, (75): 3, 711-12, 2010.
  • Scoll BJ, Uzzo RG, Chen DYT, Boorjian SA, Kutikov A, Manley BJ, Viterbo R: Robot Assisted Partial Nephrectomy: A large single institutional experience, Urology, 75(6):1328-34, 2010.
  • Lipton A, Uzzo RG, Amato RJ, Ellis GK, Hakimian B, Roodman GD, Smith MR: The Science and Practice of Bone Health in Oncology: Managing Bone Loss and Metastasis in Patients with Solid Tumors. J Natl Compr Canc Netw, 7; S1-S29, 2009.
  • Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DYT, Viterbo R, Greenberg RE, Wong YN, Raman JD, Boorjian SA: Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int, [E-pub ahead of print], 2009.
  • Uzzo RG: Editorial Comment: Laparoscopy and Robotics. Urology, 74(5), November, 2009.
  • Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin S, Russo P, Uzzo RG: Guideline for Management of the Clinical T1 Renal Mass. J Urol, 182(4):1271-9, 2009.
  • Kunkle DA, Kutikov A, and Uzzo RG: Management of small renal masses. Semin Ultrasound CT MR, 30(4): 352-8, 2009.
  • Chen DY, Uzzo RG: Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance. J Natl Compr Canc Netw, 7: 635, 2009.
  • Kutikov A, Uzzo RG. The RENAL Nephrometry Score: A Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth. J Urol, 182(3):844-53, 2009.
  • Uzzo RG: Laparoscopic Partial Nephrectomy in Octogenarians – Can a “Small” Knife extend a “Long” Life? Urology 74(5), 1044-5, 2009.
  • Wong YN, Freedland SJ, Egleston B, Vapiwala N, Uzzo RG, Armstrong K: The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol, 56(4):609-16, 2009.
  • Scoll B, Crispen P, Wong YN, Egleston B, Saad I, Uzzo RG: Age, tumor size, and relative survival in localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol, 181 (2): 506-11, 2009.
  • Rothman J, Egleston B, Wong YN, Iffrig K, Lebovitch S, Uzzo RG: Histopathologic characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis, J Urol, 181 (1): 29-34, 2009.
  • Kunkle DA, Uzzo RG, Cadeddu JA. Cryoablation or Radiofrequency Ablation of the Small Renal Mass: A Meta-Analysis Editorial Comment. J Urol, 181(4):1601-2, 2009.
  • Boorjian SA, Uzzo RG: The evolving management of small renal masses. Curr Oncol Rep, 11(3):211-7, 2009.
  • Giri V, Egleston B, Ruth K, Uzzo RG, Chen DYT, Buyyounouski M, Raysor S, Hooker S, Torres J, Ramike T, Mastalski K, Kim T, Kittles R: Race, Genetic West African Ancestry, and Prostate Cancer Prediction by PSA in Prospectively Screened High-Risk Men. Cancer Prev Res, (2): 244-250, 2009.
  • Crispen PL, Boorjian SA, Viterbo R, Chen DYT, Uzzo RG: Natural History, Growth Kinetics and Outcomes of Untreated Clinically Localized Renal Tumors Under Active Surveillance, Cancer, 115 (13): 2844-52, 2009.
  • Cooperberg MR, Hinotsu S, Chancellor MB, Homma Y, Nelson PS, Matsuyama H, Menon M, Kucuk O, Hara I, Egawa S, Uzzo RG, Kanayama HO, Okuyama A, Akaza H: Fourth joint meeting of the American Urological Association and the Japanese Urological Association Specialty Society program at the 104th annual meeting of the American Urological Association at Chicago 2009. Int J Urol, 16(8): 703-8, 2009.
  • Kutikov A, Kunkle D, Uzzo RG: Focal therapy for kidney cancer: a systematic review. Current Opinions in Urology, 19 (2): 148-53, 2008.
  • Makhov P, Golovine K, Uzzo RG, Wuestefeld T, Scoll BJ, Kolenko VM: Transcriptional regulation of the major zinc uptake protein hZip1 in prostate cancer cells. Gene, 431(1-2):39-46, 2008.
  • Uzzo RG, Rohde D. Results of the phase III Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGETs) evaluating sorafenib in metastatic clear cell kidney cancer – implications for the urologist. Urol Onc, (submitted), 2008.
  • Golovine K, Makhov P, Uzzo RG, Shaw T, Kunkle D, Kolenko VM: Overexpression of the zinc uptake transporter hZIP1 inhibits NF-κB and reduces the malignant potential of prostate cancer cells in vitro and in vivo. Clin Cancer Res, 14: 5376-84, 2008.
  • Makhov P, Golovine K, Uzzo RG, Rothman J, Crispen PL, Shaw T, Scoll BJ: Zinc chelation induces rapid depletion of the X-linked inhibitor of apoptosis and sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Cell Death Differ, 15(11):1745-51, 2008.
  • Crispen PC, Wong YN, Greenberg RE, Chen DYT, Uzzo RG: Predicting growth of solid renal masses under active surveillance. Urol Oncol, 26: 555-9, 2008.
  • Kunkle DA, Egleston BL, Uzzo RG: Cryoablation vs. radiofrequency ablation of the small renal mass: A meta-analysis of published literature. Cancer, 113(10):2671-2680, 2008.
  • Golovine K, Uzzo RG, Makhov P, Crispen PLP, Shaw T, Kunkle D, Kolenko VM: Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappaB- dependent pathway. Prostate, 68: 1443-9, 2008.
  • Uzzo, RG: Renal Masses: To treat or not to treat – if that is the question are contemporary biomarkers the answer? J Urol, 180 (2): 433-4, 2008.
  • Haas NB, Uzzo RG: Adjuvant therapy for renal cell carcinoma. Current Oncol Rep, 10(3):245-52, 2008.
  • Kunkle DA, Egelston B, Uzzo RG: Re: Excise, ablate or observe the small renal mass: Moving away from “it works” toward critical assessments with meaningful oncologic endpoints. J Urol, 180 (4): 1568, 2008.
  • Rothman J, Crispen PL, Wong YN, Al-Saleem T, Fox EB, Uzzo RG: Pathologic concordance of sporadic synchronous bilateral masses. Urology, (72) 1: 138-42, 2008.
  • Kaplan DJ, Crispen PL, Greenberg RE, Chen DYT, Viterbo R, Buyyounouski MK, Horwitz EM, Uzzo RG: Residual prostate cancer after radiotherapy: a study of radical cystoprostatectomy specimens. Urology, 72 (3): 654-8, 2008.
  • D'Ambrosio DJ, Ruth K, Horwitz, EM, Uzzo RG, Pollack A, Buyyounouski MK: How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier? Int. J Rad Onc Bio Phys, 70 (5): 1487-91, 2008.
  • Abramowitz MC, Li TN, Buyyounouski MK, Ross E, Uzzo RG, Pollack A and Horwitz EM. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer; 112 (1): 55-60, 2008.
  • Uzzo RG, Haas NB, Crispen PL, Kolenko V: Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone refractory prostate cancer. Cancer, 112 (8): 1660-71, 2008.
  • Uzzo RG: Is CT-guided percutaneous radiofrequency ablation oncologically effective in patients with renal cell carcinoma? Nat Clin Prac Urol, 1 (5): 18-9, 2008.
  • Kunkle DA, Egleston BL, Uzzo RG: Excise, ablate or observe: the small renal mass dilemma – a meta-analysis and review. J Urol, 179 (4):1227-33, discussion 1233-4, 2008.
  • Crispen PL, Viterbo R, Fox EB, Greenberg RE, Chen DYT, Uzzo RG: Delayed intervention of small sporadic renal masses undergoing active surveillance. Cancer, 112 (5):1051-57, 2008.
  • Cairns, P, Uzzo, RG: Methylation-based detection of kidney cancer. Cancer Biomarkers 4:136-137, 2008.
  • Haas NB, Kunkle DA, Uzzo RG: Adjuvant therapy for high risk renal carcinoma patients. Current Oncol Rep, 8 (1): 19, 2007.
  • Crispen PL, Greenberg RE, Chen DY, Uzzo RG: Observation of small renal masses. Russian Journal of Urology 4: 17-21, 2007.
  • Haas NB, Uzzo RG: Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer. Curr Treat Options Oncol 8(3): 211-26, 2007.
  • Haas NB, Uzzo RG: Targeted therapies for kidney cancer in urologic practice. Urologic Oncology: 25 (5): 420-32, 2007.
  • Giri V, Beebe-Dimmer J; Buyyounouski M, Konski A, Feigenberg SJ , Uzzo RG, Hanks G, Godwin A, Chen DYT, Gordon R, Cescon T, Raysor R; Watkins Bruner D: Prostate cancer risk assessment program – a ten-year update of cancer detection. J Urol 178 (5): 1920-24, 2007.
  • Haas NB, Uzzo RG: ECOG 2805: A Randomized, double blind phase III trial of adjuvant Sunitinib versus Sorafenib versus placebo in patients with resected renal cell carcinoma. US Genitourinary Disease (2), 2006.
  • Kunkle DA, Haas NB, Uzzo RG: Adjuvant strategies for high risk renal cell carcinoma patients. Current Urology Reports, 8 (1): 19-30, 2007.
  • Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A: Radiation dose and late failures in prostate cancer. Int. J Rad Onc Bio Phys 67 (4): 1074-81, 2007.
  • Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A: Timing of biochemical failure and distant metastases for low, intermediate and high risk prostate cancer after radiotherapy. Cancer 110 (1): 68-80, 2007.
  • Kunkle DA, Crispen PL, Chen DY, Greenberg RE, Uzzo RG: Enhancing renal masses with zero net growth during active surveillance. J Urol 177 (3): 849-54, 2007.
  • Kunkle DA, Cripsen PL, Uzzo RG: Tumor size predicts synchronous metastases in renal cell carcinoma: Implications for surveillance of small renal masses. J Urol 177 (5): 1692-96, 2007.
  • Crispen PL, Uzzo RG: The natural history of untreated renal masses. Brit J Urol 99 (5): 1203-07, 2007.
  • Crispen PL, Uzzo RG: Renal cell carcinoma: can some be observed? Contemporary Urology 19 (5): 10-17, 2007.
  • D'Ambrosio DJ, Hanlon AL, Feigenberg, SJ,Horwitz EM, Uzzo RG, Pollack A, Buyyounouski MK: The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int. J Rad Onc Bio Phys. 67 (4): 1082-87, 2007.
  • Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM: Vitamin E Succinate inhibits NF-κB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Prostate 67 (6): 582-90, 2007.
  • Dulaimi E, Uzzo RG, Ibanez de Caceres I, Greenberg RE, Al-Saleem T, Cairns P: Monitoring of tumor suppressor gene methylation in urine from follow-up renal cancer patients. Nat Rev Cancer, 7 (7):531-543, 2007.
  • Ibanez de Caceres, I, Dulaimi, E, Hoffman, AM, Al-Saleem, T, Uzzo, RG, Cairns, P: Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Research, 66 (10); 5021, 2006.
  • Uzzo RG, Crispen PL, Golovine K, Makhov P, Horwitz EM, Kolenko V: Diverse effects of zinc on transcriptional control of NF-kB and AP-1:implications for prostate cancer progression Carcinogenesis 27 (10): 1980-90, 2006.
  • Halbert RJ, Figlin RA, Atkin MB, Bernal M, Hutson TE, Uzzo RG, Bukowski RM, Khan KD, Wood CG, Dubois R: Treatments for patients with metastatic renal cell cancer: A Rand Appropriateness Panel. Cancer. 107 (10): 2375-83, 2006.
  • Matin SF, Ahrar K, Cadeddu JA, Gervais DA, McGovern FJ, Zagoria RA, Uzzo RG, Haaga J, Resnick MI, Kaouk J, Gill IS: Residual and recurrent disease following renal energy ablative therapy: implications for management – a multi-institutional study. J Urol 176 (5): 1973-77, 2006.
  • Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Konski AA, Movsas B, Greenberg RE, Uzzo RG, Ma CM, McNeeley SW, Buyyounouski M, Price RA: Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int. J Rad Onc Bio Phys. 64 (2): 518-26, 2006.
  • Chawla S, Crispen P, Hanlon A, Greenberg RE, Chen D, Uzzo RG: The natural history of enhancing renal masses: A meta-analysis and review of the world literature. J Urol. 175 (2): 425-31, 2006.
  • Feigenberg SJ, Hanlon A, Horwitz E, Uzzo RG, Eisenberg D, Pollack A: A PSA bounce of greater than 1.4 ng/ml is clinically significant following external beam radiotherapy for prostate cancer. Amer J Clin Oncol. 29 (5): 458-62, 2006.
  • Feigenberg SJ, Hanlon AL, Horwitz EM; Uzzo RG; Pollack A.: Long term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three dimensional conformal radiation therapy, J Rad Onc Bio Phys. 62 (2): 397-405, 2005.
  • Uzzo RG: Renal Cell Carcinoma: Urologists in a New Era J Urol. 174: 1723, 2005.
  • Uzzo RG: Does pathological stage affect the prognosis for patients with clinically staged T1 renal cell carcinoma? Nature Clinical Practice Urology 2 (5): 211-213, 2005.
  • Watkins Bruner D., Linton S., Konski A., Uzzo RG, Greenberg RE, Pollack A, Gordon R., Cescon TP, Daly M, Young W., Goplerud J, Higman-Tofani S, Engstrom P: Successful strategies for African American recruitment to prostate cancer research. Int J Canc Prev 1(4): 295-306, 2005.
  • Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A: Defining biochemical failure following radiation therapy with and without androgen deprivation for prostate cancer. Int. J Rad Onc Bio Phys.63:5, 1455, 2005.
  • Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A: Role of prostate dose escalation in patients with > 15% risk of pelvic lymph node involvement. Int J. Radiation Oncology Biol Phys, 61 (3); 695-701, 2005.
  • Andrews SF, Horwitz EM, Feigenberg SJ, Eisenberg DF, Hanlon AL, Uzzo RG, Pollack A: Does a delay in initiation of external beam radiation therapy after tissue diagnosis effect outcome for men with prostate cancer? Cancer 104 (2): 299-304, 2005.
  • Yamaguchi K, Uzzo RG, Pimkina J, Golovine K, Makhov P, Kolenko VM: Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene 24: 5868, 2005.
  • Viterbo R, Greenberg RE, Al-Saleem T, Uzzo RG: Prior abdominal surgery and radiation do not complicate the retroperitoneoscopic approach to the kidney or adrenal gland. J Urol. 174 (2): 446-450, 2005.
  • Buyyounouski MK, Hanlon AL, Horwitz EM, Uzzo RG, Pollack A.: Biochemical failure and the temporal kinetics of prostate specific antigen following radiation therapy with androgen deprivation. J Rad Onc Bio Phys. 61(5): 1291-1298, 2005.
  • Feigenberg SJ; Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A: What pretreatment PSA warrants long term androgen deprivation? J Rad Onc Bio Phys. 61 (4): 1003-10, 2005.
  • Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A: Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int. J Rad Onc Bio Phys. 61 (3):695-701, 2005.
  • Manne, SL, Ostroff, JS, Winkel, G, Fox, K, Grana, G, Miller, E, Ross, S, Frazier, T, Buyyounouski, MK, Hanlon, AL, Eisenberg, DF, Horwitz, EM, Feigenberg, SJ, Uzzo, RG, Pollack, A, Morrow, M, Chen, JQ, Yager, JD, Russo, J, Bassi, DE, Fu, J, Lopez de Cicco, R, Klein-Szanto, AJ, Devlin, J, Sherman, E, Altomare, DA, Vaslet, CA, Skele, KL, De Rienzo, A, Devarajan, K, Jhanwar, SC, McClatchey, AI, Kane, AB, Testa, JR, Murphy, ME, Langer, CJ, Mehta, MP, Viterbo, R, Greenberg, RE, Al Saleem, T, Canutescu, AA, Dunbrack, RL, Jr., Serebriiskii, IG, Fang, R, Latypova, E, Hopkins, R, Vinson, C, Joung, JK, Golemis, EA: Couple-focused group intervention for women with early stage breast cancer. J. Consult. Clin. Psychol. 73:634-646., 2005.
  • Feigenberg SJ, Eisenberg D, Horwitz EM, Uzzo RG, Hanlon AL, Pollack A: Post-treatment PSA values within 6 months of 3D conformal radiotherapy for prostate cancer predict distant metastases. Int. J Rad Onc Bio Phys. 60 (1): S234-35, 2004.
  • Uzzo RG, Bramwell M: Renal cell carcinoma: The role of urologists in adjuvant strategies. Am J Urol Review: Supp 11, vol 12, 2004.
  • Horwitz EM, Feigenberg SJ, Pollack A, Hanks GE, Uzzo RG: re: Androgen suppression plus radiation therapy for prostate cancer. JAMA: 292 (17), 2084-85, 2004.
  • Yamaguchi K, Uzzo RG, Finke JH, Kolenko V: Renal carcinoma cells undergo apoptosis without oligonucleospmal DNA fragmentation. Biochem Biophys Res Commun. 318 (3):710, 2004.
  • Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer, 100(3): 538, 2004.
  • Kansas B, Eddy MJ, Mydlo JH, Uzzo RG: Incidence and management of penetrating renal trauma in patients with multi-organ injury: extended experience at an inner city trauma center. J Urol 172 (4):1355-60, 2004.
  • Horwitz EM, Feigenberg SJ, Uzzo RG: The treatment of non-metastatic prostate cancer with external beam radiation therapy. Minerv Urol. Nephrol. 56(2): 173-188, 2004.
  • Mueller TJ, Wu H, Greenberg RE, Hudes G, Topham N, Lessin SR, Uzzo RG: Cutaneous metastases from genitourinary malignancies Urol 63(6): 1021-6, 2004.
  • Uzzo RG: Re: Prostate Cancer – 3rd International Consultation on Prostate Cancer. BJU Int 93(6):885-886, 2004.
  • Dulaimi E, de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polasick T, Babb JS, Cairns P: Promoter hypermethylation profile of kidney cancer. Clin Canc. Res. 10 (12): 3972-79, 2004.
  • Buyyounouski M, Horwitz E, Hanlon A, Uzzo R, Pollack A: Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database. J Urol. 171(3): 1246, 2004.
  • Al-Saleem T, Cairns P, Dulaimi EA, Feder M, Testa JR, Uzzo RG: The genetics of renal oncocytosis: A possible model for neoplastic progression. Cancer Genet. Cytogenet. 152 (1):23-8, 2004.
  • Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P: Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin. Cancer Res 15;10 (6):1887-93, 2004.
  • Uzzo RG, Brown JG, Horwitz EM, Hanlon A, Mazzoni S, Konski A, Greenberg RE, Pollack A, Kolenko VM, Watkins-Bruner D: Prevalence and patterns of self-initiated nutritional supplementation in men at high risk for prostate cancer. BJU Int 93 (7):955-960, 2004.
  • Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE: Prostate cancer radiotherapy dose response: An update of the Fox Chase Experience. J Urol. 171 (3): 1132, 2004.
  • Buyyounouski MK, Horwitz EM, Price RA, Hanlon AL, Uzzo RG, Pollack A: Intensity modulated radiation therapy with MRI-simulation to reduce doses received by erective tissues during prostate cancer treatment. Int J Radiat Oncol Biol Phys. 58 (3):743-9, 2004.
  • Buyyounouski MK, Horwitz EM, Uzzo RG, Price RA, McNeeley SW, Azizi D, Hanlon AL, Milestone B, Pollack A: The radiation doses to erectile tissues defined with MRI- after intensity modulated radiation therapy or iodine-125 brachytherapy alone. Int. J. Radiation. Oncology. Biol. Phys. 59 (5): 1383-91, 2004.
  • Kramer NM, Horwitz EM, Uzzo RG, Hanlon AL, Hanks GE: Matched-cohort analysis of patients with prostate cancer followed with observation or treated with 3D conformal radiation therapy. Brit. J. Urol. 94 (1): 59-62, 2004.
  • Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA: Radiation therapy dose escalation for prostate cancer: A rationale for IMRT. World J. Urol. 21(4): 200, 2003.
  • Diefenbach MA, Hamrick N, Uzzo RG, Pollack A, Horwitz E, Greenberg R, Engstrom PE: Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with early-stage prostate cancer. J Urol. 170 (1): 166-169, 2003.
  • Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz E: Biochemical failure as a determinant of distant metastases and death in prostate cancer treated with radiotherapy. Int J. Radiation Oncology Biol Phys. 57 (1): 19-23, 2003.
  • Nguyen KH, Horwitz EM, Hanlon AL, Uzzo RG, Pollack A: Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer? Int J Radiat Oncol Biol Phys. 57(2): 377-83, 2003.
  • Battagli C, Uzzo RG, Dulaimi E, Krassenstein RE, Al-Saleem T, Greenberg RE, Cairns P: Detection of renal cancer in urine by a tumor suppressor gene hypermethylation panel. Cancer Res. 63:8695-8699, 2003.
  • Buyyounouski MK, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE, Pollack A: Positive prostate biopsy laterality and implications for staging. Urology 62:298-303, 2003.
  • Horwitz EM, Uzzo RG, Hanlon AL, Greenberg RE, Hanks GE, Pollack A: Modifying American Society for Therapeutic Radiology and Oncology Definition of biochemical failure to minimize influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. J Urol. 169 (3): 2153-2159, 2003.
  • Horwitz EM, Mitra RK, Uzzo RG, Das IJ, Pinover WH, Hanlon AL, McNeeley SW, Hanks GE: Impact of target volume coverage with RTOG-98-05 guidelines for transrectal ultrasound guided permanent I-125 prostate implants. Radiother. Oncol. 66 (2):173-179, 2003.
  • Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE: Validation of a treatment policy for PSA failures following 3D conformal prostate radiation therapy. Cancer 97:1127-1133, 2003.
  • Uzzo RG, Pinover WH, Horwitz EM, Parlanti A, Mazzoni S, Raysor S, Mirchanandi I, Greenberg RE, Pollack A, Hanks GE, Watkins-Bruner D: Free PSA improves prostate cancer detection in a high risk population of men with a normal total PSA and digital rectal exam. Urology. 61 (4), 754-759, 2003.
Top